Background. Immune-mediated factors such as acute cellular rejections and donor-specific antibodies (DSAs) are risk factors for cardiac allograft vasculopathy (CAV). We studied a national cohort with a unified setting and thorough protocol endomyocardial biopsy (EMB) data for an association between cellular rejections, especially when mild and recurrent, and DSAs with CAV in pediatric heart transplant (HTx) patients. Methods. This is a retrospective, national cohort study of 94 pediatric HTxs performed between 1991 and 2019 and followed until December 31, 2020. Diagnosis of CAV was based on reevaluation of angiographies. Protocol and indication EMB findings with other patient data were collected from medical records. Associations between no...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant recipien...
Cardiac allograft vasculopathy (CAV) is a leading limiting factor to long -term survival after cardi...
Biopsy‐diagnosed pAMR has been observed in over half of pediatric HT recipients within 6 years of tr...
Background. Immune-mediated factors such as acute cellular rejections and donor-specific antibodies ...
We studied 361 patients, to evaluate risk factors for cardiac allograft vasculopathy (CAV) onset a...
To evaluate the association between mild acute cellular rejection (ACR) and the development of cardi...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is the leading cause of chronic allograft loss afte...
ObjectivesThis study sought to evaluate the outcome and prevalence of viral endomyocardial infection...
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft ...
Chronic allograft vasculopathy (CAV) limits the life span of paediatric heart transplant recipients....
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after hea...
International audienceIntroduction: De novo anti-HLA donor specific antibodies (DSA) have been incon...
Abstract Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure ...
Background—Cardiac allograft vasculopathy is the major limiting factor to the long-term success of p...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant recipien...
Cardiac allograft vasculopathy (CAV) is a leading limiting factor to long -term survival after cardi...
Biopsy‐diagnosed pAMR has been observed in over half of pediatric HT recipients within 6 years of tr...
Background. Immune-mediated factors such as acute cellular rejections and donor-specific antibodies ...
We studied 361 patients, to evaluate risk factors for cardiac allograft vasculopathy (CAV) onset a...
To evaluate the association between mild acute cellular rejection (ACR) and the development of cardi...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is the leading cause of chronic allograft loss afte...
ObjectivesThis study sought to evaluate the outcome and prevalence of viral endomyocardial infection...
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft ...
Chronic allograft vasculopathy (CAV) limits the life span of paediatric heart transplant recipients....
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after hea...
International audienceIntroduction: De novo anti-HLA donor specific antibodies (DSA) have been incon...
Abstract Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure ...
Background—Cardiac allograft vasculopathy is the major limiting factor to the long-term success of p...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant recipien...
Cardiac allograft vasculopathy (CAV) is a leading limiting factor to long -term survival after cardi...
Biopsy‐diagnosed pAMR has been observed in over half of pediatric HT recipients within 6 years of tr...